The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | New trends in myeloma
Meral Beksac, MD, Ankara University, Ankara, Turkey, provides an insight into new trends in multiple myeloma as seen in this year’s American Society of Hematology (ASH) annual meeting, including the strides taken in biological therapies and new molecules that can direct immunologic responses to cancer. Furthermore, Dr Beksac highlights the importance of sequential therapies in multiple myeloma and approaches that are currently being evaluated. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Meral Beksac, MD, is on the advisory board and/or the speakers bureau for Amgen, BMS, Janssen, Sanofi, Takeda and Oncopeptides.
